Precigen (PGEN) Non-Current Assets (2012 - 2026)
Precigen (PGEN) reported Non-Current Assets of $37.0 million for Q1 2026, down 16.36% year-over-year from $44.2 million in Q1 2025, and down 8.23% quarter-over-quarter from $40.3 million in Q4 2025.
Precigen (PGEN) Non-Current Assets (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Non-Current Assets data on file, last reported at $37.0 million in Q1 2026.
- Non-Current Assets for Q1 2026 came in at $37.0 million, down 16.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $158.0 million (down 14.78% YoY), and the FY2025 annual result was $40.3 million, down 6.03% from the prior year.
- Non-Current Assets declined to $37.0 million in Q1 2026 per PGEN's latest filing, from $40.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $180.6 million in Q1 2022 and troughed at $37.0 million in Q1 2026.
- A 5-year average of $79.2 million and a median of $82.3 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets plunged 56.91% in 2022, then rose 1.31% in 2023.
- A 5-year view of Non-Current Assets shows it stood at $97.8 million in 2022, then retreated by 15.88% to $82.3 million in 2023, then slumped by 47.92% to $42.9 million in 2024, then retreated by 6.03% to $40.3 million in 2025, then dropped by 8.23% to $37.0 million in 2026.
- Business Quant data shows PGEN's Non-Current Assets at $37.0 million in Q1 2026, $40.3 million in Q4 2025, and $41.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 39.71 Mn |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | 36.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.96 Mn |
| Dec 31, 2025 | 40.27 Mn |
| Sep 30, 2025 | 41.67 Mn |
| Jun 30, 2025 | 39.14 Mn |
| Mar 31, 2025 | 44.19 Mn |
| Dec 31, 2024 | 42.85 Mn |
| Sep 30, 2024 | 48.96 Mn |
| Jun 30, 2024 | 49.45 Mn |
| Mar 31, 2024 | 85.30 Mn |
| Dec 31, 2023 | 82.29 Mn |
| Sep 30, 2023 | 97.70 Mn |
| Jun 30, 2023 | 101.90 Mn |
| Mar 31, 2023 | 103.80 Mn |
| Dec 31, 2022 | 97.82 Mn |
| Sep 30, 2022 | 96.44 Mn |
| Jun 30, 2022 | 156.61 Mn |
| Mar 31, 2022 | 180.63 Mn |
| Dec 31, 2021 | 203.23 Mn |
| Sep 30, 2021 | 223.81 Mn |
| Jun 30, 2021 | 245.89 Mn |